Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Early access program for Tedopi in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) after immune checkpoint inhibitor (ICI) failure

Next Previous
Trial Profile

Early access program for Tedopi in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) after immune checkpoint inhibitor (ICI) failure

Status: Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 08 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OSE 2101 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Expanded access; Therapeutic Use

Most Recent Events

  • 08 Mar 2023 New trial record
  • 01 Mar 2023 According to an OSE Immunotherapeutics media release, the company received New Approval from the Spanish Drug Agency for an Early Access Program for Tedopi that will allow access to Tedopi through a Special Situation Authorization(1) in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) after immune checkpoint inhibitor (ICI) failure, based on data from ATALANTE-1 trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top